100
Views
5
CrossRef citations to date
0
Altmetric
Review

Unresolved issues in diffuse large B-cell lymphomas

, &
Pages 387-402 | Published online: 10 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Shuang Jiang, Xiaobo Wang, Zhiran Zhang, Lan Sun, Yunzhu Pu, Hongjuan Yao, Jingcao Li, Yan Liu, Yingge Zhang & Weijing Zhang. (2016) CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells. International Journal of Nanomedicine 11, pages 5505-5518.
Read now

Articles from other publishers (4)

Huei-Jen Chen, Yi-An Cheng, Yu-Tung Chen, Chia-Ching Li, Bo-Cheng Huang, Shih-Ting Hong, I.-Ju Chen, Kai-Wen Ho, Chiao-Yun Chen, Fang-Ming Chen, Jaw-Yuan Wang, Steve R. Roffler, Tian-Lu Cheng & Dung-Ho Wu. (2023) Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20). Cancer Nanotechnology 14:1.
Crossref
Peipei Xu, Huaqin Zuo, Rongfu Zhou, Fan Wang, Xu Liu, Jian Ouyang & Bing Chen. (2017) Doxorubicin-loaded platelets conjugated with anti-CD22 mAbs: a novel targeted delivery system for lymphoma treatment with cardiopulmonary avoidance. Oncotarget 8:35, pages 58322-58337.
Crossref
Faramarz Naeim, P. Nagesh Rao, Sophie X. Song & Wayne W. Grody. 2013. Atlas of Hematopathology. Atlas of Hematopathology 427 438 .
Eun Ji Han, Sung-Eun Lee, Sung Hoon Kim, Hyung Sun Sohn, Seung Eun Jung, Gyeongsin Park, Byung-Ock Choi, Sang-Nam Lee, Suk-Woo Yang, Kyungja Han & Seok-Goo Cho. (2011) Clinical outcomes of post-remission therapy using 90yttrium ibritumomab tiuxetan (Zevalin®) for high-risk patients with diffuse large B-cell lymphoma. Annals of Hematology 90:9, pages 1075-1082.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.